Biomarkers play an essential role in the management of patients with invasive breast
cancer. For selecting patients likely to respond to endocrine therapy, both oestrogen …

The era of personalized medicine is likely to see an escalation in the use of biomarkers to
ensure breast cancer patients receive optimal treatment. A combination of prognostic and …

This consensus statement revises and updates the recommendations for biomarkers use in
the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society …

Breast cancer treatment has experienced several changes in the past decades due to the
discovery of specific prognostic and predictive biomarkers that enable the application of …

Current treatment of breast cancer incorporates clinical, pathological and molecular data.
Oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor …

Recent advancements in breast cancer treatment have ushered in a new era of precision
medicine. Novel trials have led to the approval of a growing list of personalized therapies …

Recommendations are presented for the routine clinical use of serum and tissue-based
markers in the diagnosis and management of patients with breast cancer. Their low …

In early breast cancer (eBC), established clinicopathological factors are not sufficient for
clinical decision making particularly regarding adjuvant chemotherapy since substantial …

The use of biomarkers ensures breast cancer patients receive optimal treatment.
Established biomarkers such as estrogen receptor (ER) and progesterone receptor (PR) …

Biomarkers play an important role in the detection and management of patients with breast
cancer. Thus, BRCA1/2 mutation testing is used for risk assessment in families with a high …